Markers of digestive cancers: Colon, rectum, pancreas, liver;Marqueurs des cancers digestifs: Côlon-rectum, pancréas, foie

Immuno-Analyse et Biologie Specialisee

Volumn 19, Issue 5 SPEC. ISS., 2004, Pages 279-285

  Eche, N ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Ad nocarcinome pancr atique; Cancer colorectaux; Colorectal cancer; Hepatocellular carcinoma; H patocarcinome; Marqueurs tumoraux; Pancreatic cancer; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ANTIGEN FUNCTION; CANCER ADJUVANT THERAPY; CANCER PATIENT; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; FOLLOW UP; KINETICS; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; PANCREAS CANCER; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; TREATMENT OUTCOME;

EID: 4744345424     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2004.07.005     Document Type: Article

References (52)

1. Adenis A., Conroy T., Lasse P., Merrouche Y., Monges G., Rivoire M., et al. Standards, options et recommandations pour la prise en charge des patients atteints de cancer du côlon. 2000. URL: http://www.fnclcc.fr/-sci/sor/.
2. Anonymous Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer J. Clin. Oncol. 14 1996 2843 2877
3. Y. Aoyagi, A. Saitoh, Y. Suzuki, K. Igarashi, M. Oguro, and T. Yokota Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis Hepatology 17 1993 50 52
4. A. Aquino, S.P. Prete, F. Guadagni, J.W. Greiner, A. Giuliani, and L. Orlando Effect of 5-fluoro-uracil on carcinoembryonic antigen expression and shedding at clonal level in colon cancer cells Anticancer Res. 20 5B 2000 3475 3484
5. R.C. Bast, P. Ravdin, D.F. Hayes, S. Bates, H. Fritsche Jr., and J.M. Jessup 2000 Update of recommendations for the use of tumour markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 19 2001 1865 1878
6. Becouarn Y., Blanc-Vincent M.P., Lasser P., Dubois J.B., Ducreux M., Giovannini M., et al. Standards, options et recommandations pour la prise en charge des patients atteints d'adénocarcinome primitif du rectum. 1998. URL: http://www.fnclcc.fr/-sci/sor/.
7. R. Broll, M. Duchrow, E. Oevermann, C. Wellm, O. Schwandner, and H. Schimmelpenning p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunochemistry in tumor tissue Int. J. Colorectal Dis. 16 1 2001 22 27
8. D.J. Bruinvels, A.M. Stiggelbout, J. Kievit, H.C. Van Houwelingen, J.D. Habbema, and C.J. Van de Velde Follow-up of patients with colorectal cancer: a meta-analysis Ann. Surg. 219 1994 174 182
9. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, and R. Lencioni Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference J. Hepatol. 35 2001 421 430
10. J. Carl, S.M. Bentzen, B. Norgaard-Pedersen, and O. Kronborg Modelling of serial carcinoembryonic antigen changes in colorectal cancer Scand. J. Clin. Lab. Invest. 53 1993 751 755
11. C. Compton, C. Fenoglio-Preiser, N. Pettigrew, and L. Fielding American Joint Comittee on Cancer Prognostic Factors Consensus Conference. Colorectal working group Cancer 88 2000 1739 1757
12. R. Cui, J. He, F. Zhang, B. Wang, H. Ding, and H. Shen Diagnostic value of protein induced by vitamin k absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetopprotein Br. J. Cancer 88 2003 1878 1882
13. M. Duffy, A. Van Dalen, C. Haglund, L. Hansson, L. Klapdor, and R. Lamerz Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines Eur. J. Cancer 39 2003 718 727
14. N. Eche, M.F. Pichon, V. Quillien, G. Gory-Delabaere, J.M. Riedinger, and J.P. Basuyau Standards, options et recommandations: marqueurs tumoraux sériques dans les cancers du côlon Bull. Cancer 88 12 2001 1177 1206
15. Fédération Francophone de Cancérologie Digestive URL. http://www.u-bourgogne.fr/FFCD/recommandations/2003chapeau.htm.
16. P. Flamen, F. Hoekstra, F. Homans, E. Van Cutsem, A. Maes, and S. Stroobants Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) Eur. J. Cancer 37 2001 862 869
17. F.L. Flanagan, F. Dehdashti, O.A. Ogunbiyi, and I.J. Kodner Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann. Surg. 227 1998 319 323
18. A. Forslund, B. Engaras, C. Lonroth, and K. Lundholm Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma Int. J. Oncol. 20 5 2002 1013 1018
19. G. Freyer, P. Rougier, R. Bugat, J.P. Droz, M. Marty, and H. Bleiberg Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients who are given irinotecan (CPT-11) as second-line chemotherapy after FU failure Br. J. Cancer 83 4 2000 431 437
20. U. Halm, T. Schulmann, I. Schieffe, H. Witzigmann, and V. Keim Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer Br. J. Cancer 82 5 2000 1013 1016
21. P. Hammel Evolution de la chimiothérapie de l'adé nocarcinome du pancréas Gastroenterol Clin. Biol. 26 2002 603 604
22. P. Hammel Tumeurs pancréatiques de découverte fortuite: diagnostic et prise en charge Gastroenterol Clin. Biol. 26 2002 700 708
23. P. Hammel, and T. Soussi Serum p53 antibody assay: evaluation in colorectal cancer Rev. Med. Interne 21 2 2000 167 173
24. M. Giovannini, D. Elias, G. Monges, J.L. Raoul, and P. Rougier Hepatocellular carcinoma Br. J. Cancer 84 2001 74 77
25. S. Gupta, S. Bent, and J. Kolwes Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis Ann. Intern. Med. 139 2003 46 50
26. K. Hanazaki, N. Kawamura, H. Sodeyama, M. Wakabayashi, S. Yokoyama, and Y. Sode Carcinoembryonic antigen and intra-arterial chemotherapy response of liver metastases Hepatogastroenterology 45 1998 462 467
27. H. Hayashi, T. Kumada, S. Nakano, I. Takeda, K. Sugiyama, and S. Kiriyama Usefulness of measurement of Lens Culinaris Agglutinin-Reactive fraction of α-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma Am. J. Gastroenterol. 94 1999 3028 3033
28. J. Henrion, E. Libon, S. De Maeght, P. Deltenre, M. Schapira, and J.M. Ghilain Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin Gastroenterol Clin. Biol 27 5 2003 534 539
29. M.N. Holten-Andersen, R.W. Stephens, H.J. Nielsen, G. Murphy, I.J. Christensen, and W. Stetler-Stevenson Clin. Cancer Res. 6 11 2000 4292 4299
30. M. Ikeda, S. Okada, K. Tokuuye, H. Ueno, and T. Okusaka Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy Cancer 91 3 2001 490 495
31. P.J. Johnson, T.C.W. Poon, N.M. Hjelm, C.S. Ho, C. Blake, and S.K.W. Ho Structures of disease-specific serum alpha-fetoprotein isoforms Br. J. Cancer 83 2000 1330 1337
32. H.J. Kim, M.J. Kim, S.J. Myung, B.C. Lim, E.T. Park, and K.S. Yoo A new strategy for the application of CA 19-9 in the differentiation of pancreatobiliary cancer: analysis using a receiver operating characteristic curve Am. J. Gastroenterol. 94 7 1999 1941 1946
33. C.H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, and E. Aranda Clinical determinants of survival in patients with 5-fluoro-uracil-based treatment for metastasis colorectal cancer: results of a multivariate analysis of 3825 patients Annals of Oncology 13 2002 308 317
34. D. Li, T. Mallory, and S. Satomura AFP-L3: a new generation of tumour marker for hepatocellular carcinoma Clin. Chim. Acta. 313 1-2 2001 15 19
35. J.A. Marrero, G.L. Su, W. Wei, D. Emick, H.S. Conjeevaram, and R.J. Fontana Desgammacarboxyprothrombin can differentiate hepatocellular carcinoma from malignant chronic liver disease in american patients Hepatology 37 5 2003 1114 1121
36. O. Micke, F. Bruns, R. Kurowski, E. Horst, A.F. DeVries, and J.W. Hausler Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy Int. J. Radiat. Oncol. Biol. Phys. 57 1 2003 90 97
37. N. Mlika-Cabanne, D. Bellet Au nom du groupe de travail réuni par l'Anaes Marqueurs sériques dans les cancers du sein et les cancers colorectaux Gastroenterol. Clin. Biol. 22 1998 442 457
38. M. Noda, M. Kusunoki, H. Yanagi, T. Yamamura, and J. Utsunomiya Serum carcinoembryonic antigne (CEA) correlates with the survival time during 5-FU hepatic arterial infusion chemotherapy for unresectable colorectal hepatic metastases Int. J. Oncol. 9 1996 741 746
39. A. Quentmeier, P. Moller, V. Schwarz, U. Abel, and P. Schlag Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver diseases treated by regional chemotherapy J. Surg. Oncol. 40 1989 112 118
40. A.G. Renehan, M. Egger, M.P. Saunders, and S. O'Dwyer Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials BMJ 324 2002 1 8
41. M. Rosen, L. Chan, R.W. Beart, P. Vukasin, and G. Anthone Follow-up of colorectal cancer: a meta-analysis Dis. Colon Rectum 48 1998 1116 1126
42. E.D. Saad, M.C. Machado, D. Wajsbrot, R. Abramoff, P.M. Hoff, and A. Katz Pretratment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine Int. J. Gastro-intest. Cancer 32 1 2002 35 41
43. G. Shiota, M. Ishida, N. Noguchi, K. Oyama, Y. Takano, and M. Okudo Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival Dig. Dis. Sci. 45 1 2000 122 128
44. H. Sorbye, and O. Dahl Carcinoembryonic antigens surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumour marker monitoring and guidelines J. Clin. Oncol. 21 23 2003 4466 4467
45. M. Soresi, C. Magliarisi, P. Campagna, G. Leto, G. Bonfissuto, and A. Riili Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma Anticancer Res. 23 2C 2003 1747 1753
46. A. Takeda, H. Shimada, K. Nakajima, S. Yoshimuar, T. Suzuki, and T. Asano Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection Int. J. Clin. Oncol. 6 1 2001 45 49
47. R. Tang, M.C. Ko, J.Y. Wang, C.R. Changchien, H.H. Chen, and K.C. Hsu Humoral response to p53 in human colorectal tumours: a prospective study of 1209 patients Int. J. Cancer 94 6 2001 859 863
48. P. Therasse, G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New Guidelines to evaluate the response to treatment in solid tumors J. Natl. Cancer Inst. 92 2000 205 216
49. F. Trevisani, P.E. D'Intino, A.M. Morselli-Labate, G. Mazella, E. Accogali, and P. Caraceni Serum α-fetoprotein for diagnosis of hepatocellular carcinoma with chronic liver disease: influence of HbsAg and anti-HCV status J. Hepatol 34 2001 570 575
50. UICC [Union Internationale Contre le Cancer] L.H. Sobin, and C. Wittekin TNM: Classification des tumeurs malignes 2003 Cassini Paris
51. Wun Y.T., Dickinson J.A. Cochrane database Syst. Rev. 2003; 2: CD002799.
52. S. Zucker, R.M. Lysik, B.I. Di Massimo, H.M. Zarrabi, U.M. Moll, and R. Grimson Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer Cancer 76 1995 700 708